The Food and Drug Administration is investigating serious adverse events involving Limbrel, a capsule being marketed as a medical food to manage the metabolic processes associated with osteoarthritis. Health care providers who know their patients are taking the product should advise them to stop taking it immediately, FDA said. While a range of adverse events have been reported, two serious and potentially life-threatening medical conditions are among them: drug-induced liver injury and hypersensitivity pneumonitis. For more information, see the FDA safety alert.

Related News Articles

Headline
Reps. Bradley Schneider, D-Ill., Don Bacon, R-Neb., and Abby Finkenauer, D-Iowa, yesterday introduced a House companion to AHA-supported legislation that would…
Insights and Analysis
Also in this weekly roundup of nursing news: a nurse helps save the life of a man at the theatre, and executive moves in the field.
Blog
During National Nurses Week, Robyn Begley, AHA Senior Vice President and Chief Nursing Officer and CEO of AHA’s American Organization of Nurse Executives,…
Blog
In this AHA Stat blog post, Elisa Arespacochaga, vice president of the AHA Physician Alliance, highlights strategies from four female physicians who…
Headline
During National Nurses Week, which kicks off today, AHA and its American Organization of Nurse Executives subsidiary celebrate nurses for the invaluable role…
Insights and Analysis
Also in this weekly roundup of nursing news: A Florida nurse saves the life of a nearly drowned girl.